AMEXInformation TechnologyComputer HardwareSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improvement in operating leverage to reduce losses | Operating losses are improving, showing progress on costs. | Intact | Operating loss reduction stalls or reverses by 2026-Q3 | Operating income: $-5.606M FY2026-Q2; GAAP. Published target: Operating loss reduced by at least 40% from 2025-Q4 levels by 2026-Q3. Target and observation units differ. Source published Aug 14, 2026-5,605,631 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0141a0a2-31f3-4c64-a057-7a7bfa3f7f76. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Operating income improved from -$8.5 million in 2025-Q4 to -$5.1 million in 2026-Q1, reflecting progress in managing costs while investing for growth. Management continues to balance cost discipline with strategic investments, indicating delivering trajectory. Delivery assessment Oct 24, 2026 |
Revenue growth and normalization by end of 2026-Q3 | A primary condition in AgEagle Aerial Systems Inc's published investment case. The stated target is >0% YoY growth by 2026-Q3. | Broken | YoY revenue growth remains negative through 2026-Q3 | Revenue growth: -36.01% FY2026-Q2; GAAP. Published target: >0% YoY growth by 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 14, 2026-36.01115 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0141a0a2-31f3-4c64-a057-7a7bfa3f7f76. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Revenue grew from $1.4 million in 2026-Q1 to $2.7 million in 2026-Q2, nearly doubling sequentially. Management expects revenue to normalize and grow by the end of 2026-Q3, reflecting delivery on the stated growth trajectory. Delivery assessment Oct 24, 2026 |
Successful execution of strategic partnerships for growth | AgEagle is forming strategic partnerships to grow its market. | Improving | Partnerships fail to generate revenue or are dissolved by 2026-Q4 | 1 partnership active vs >=2 target April 2026 8-K confirms ThirdEye investment and JV agreement. No news of second partnership or dissolution. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Management executed a $10 million investment in ThirdEye Systems and formed the ThirdEye USA joint venture with 51% ownership, plus a strategic investment in Aerodrome Group Ltd. These moves broaden EagleNXT's defense market reach and product portfolio. The trajectory is delivering as the joint venture became operational and new capabilities were added. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business, not an established compounder, because it remains loss-making and recent financial performance is weak. The multi-year thesis is in a watch state: partnerships and revenue growth offer progress, but management volatility and elevated risk leave execution uncertain.
The valuation model shows a premium versus peers, while its expectations gap is negative, meaning market expectations appear above the model’s view of fundamentals. Valuation has fallen recently, and the priced-in assessment is tagged justified, with low fragility; the evidence does not show that the valuation is cheap.
Near-term results could remain uneven: revenue rose from the first to the second quarter of 2026, and management expects growth by the end of the third quarter, while operating losses have narrowed from the fourth quarter of 2025 to the first quarter of 2026. However, recent performance is weak relative to the industry cohort, and the evidence flags elevated risk of another earnings miss; a guidance cut would be a meaningful negative.
The multi-year view hinges on whether revenue growth continues, partnerships add useful defense capabilities, and operating losses keep narrowing. Near term, guidance and delivery are key swing factors; broader support could come if the Fed cuts rates or technology bellwethers keep reporting strong results, though those conditions do not resolve UAVS’s company-specific risks.
Over the next 1 to 3 years, UAVS has signs of business progress but remains a high-risk, loss-making company with weak recent performance and demanding expectations. The thesis depends on sustained execution, with the next guidance and earnings updates important near-term tests. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.